CN104114153A - 用于将治疗剂递送至脑瘤的细菌衍生的、完整的微细胞 - Google Patents

用于将治疗剂递送至脑瘤的细菌衍生的、完整的微细胞 Download PDF

Info

Publication number
CN104114153A
CN104114153A CN201280069592.1A CN201280069592A CN104114153A CN 104114153 A CN104114153 A CN 104114153A CN 201280069592 A CN201280069592 A CN 201280069592A CN 104114153 A CN104114153 A CN 104114153A
Authority
CN
China
Prior art keywords
minicells
brain
tumor
drug
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280069592.1A
Other languages
English (en)
Chinese (zh)
Inventor
H·布拉姆巴特
J·麦克迪尔米德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EnGeneIC Molecular Delivery Pty Ltd
Original Assignee
EnGeneIC Molecular Delivery Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EnGeneIC Molecular Delivery Pty Ltd filed Critical EnGeneIC Molecular Delivery Pty Ltd
Priority to CN201811227385.XA priority Critical patent/CN109125286A/zh
Publication of CN104114153A publication Critical patent/CN104114153A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1203—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules in a form not provided for by groups A61K51/1206 - A61K51/1296, e.g. cells, cell fragments, viruses, virus capsides, ghosts, red blood cells, viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201280069592.1A 2011-12-13 2012-12-12 用于将治疗剂递送至脑瘤的细菌衍生的、完整的微细胞 Pending CN104114153A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811227385.XA CN109125286A (zh) 2011-12-13 2012-12-12 用于将治疗剂递送至脑瘤的细菌衍生的、完整的微细胞

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161569907P 2011-12-13 2011-12-13
US61/569,907 2011-12-13
PCT/IB2012/002950 WO2013088250A1 (en) 2011-12-13 2012-12-12 Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201811227385.XA Division CN109125286A (zh) 2011-12-13 2012-12-12 用于将治疗剂递送至脑瘤的细菌衍生的、完整的微细胞

Publications (1)

Publication Number Publication Date
CN104114153A true CN104114153A (zh) 2014-10-22

Family

ID=48611925

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280069592.1A Pending CN104114153A (zh) 2011-12-13 2012-12-12 用于将治疗剂递送至脑瘤的细菌衍生的、完整的微细胞
CN201811227385.XA Pending CN109125286A (zh) 2011-12-13 2012-12-12 用于将治疗剂递送至脑瘤的细菌衍生的、完整的微细胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201811227385.XA Pending CN109125286A (zh) 2011-12-13 2012-12-12 用于将治疗剂递送至脑瘤的细菌衍生的、完整的微细胞

Country Status (23)

Country Link
US (3) US9844598B2 (enExample)
EP (1) EP2790668B1 (enExample)
JP (2) JP6522340B2 (enExample)
KR (2) KR20140102294A (enExample)
CN (2) CN104114153A (enExample)
AU (2) AU2012351743B2 (enExample)
CA (1) CA2858315C (enExample)
CY (1) CY1123824T1 (enExample)
DK (1) DK2790668T3 (enExample)
ES (1) ES2843402T3 (enExample)
HR (1) HRP20201930T1 (enExample)
HU (1) HUE052136T2 (enExample)
IL (1) IL233031B (enExample)
LT (1) LT2790668T (enExample)
MX (2) MX385832B (enExample)
PT (1) PT2790668T (enExample)
RS (1) RS61161B1 (enExample)
RU (1) RU2664698C2 (enExample)
SG (2) SG11201403062YA (enExample)
SI (1) SI2790668T1 (enExample)
SM (1) SMT202000676T1 (enExample)
TW (1) TWI627966B (enExample)
WO (1) WO2013088250A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106999444A (zh) * 2014-10-03 2017-08-01 安吉尼科分子传输公司 完整的细菌衍生的囊泡对小分子化合物的增强装载
CN114099686A (zh) * 2014-07-15 2022-03-01 约翰·霍普金斯大学 源自骨髓的抑制细胞的抑制和免疫检查点阻断

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1583562E (pt) * 2003-01-06 2011-09-19 Angiochem Inc Angiopep-1, compostos relacionados, e suas utilizações
US9365634B2 (en) * 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
PT2279008T (pt) 2008-04-18 2019-05-20 Angiochem Inc Composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e utilização
CN102245642A (zh) 2008-10-15 2011-11-16 安吉奥开米公司 Glp-1激动剂的结合物及其用途
CN102245636A (zh) 2008-10-15 2011-11-16 安吉奥开米公司 用于药物递送的依托泊苷和多柔比星结合物
BRPI0922689A2 (pt) 2008-12-05 2018-11-06 Angiochem Inc. conjugados de neurotensina ou análogos de neurotensina e usos dos mesmos
CN102300987A (zh) 2008-12-17 2011-12-28 安吉奥开米公司 膜型-1基质金属蛋白抑制剂及其用途
ES2729261T3 (es) 2009-04-20 2019-10-31 Angiochem Inc Tratamiento del cáncer de ovario utilizando un agente anticancerígeno conjugado con un análogo de Angiopep-2
JP5932642B2 (ja) 2009-07-02 2016-06-08 アンジオケム インコーポレーテッド 多量体ペプチドコンジュゲートおよびその使用
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RS63430B1 (sr) 2010-10-01 2022-08-31 Modernatx Inc Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK3682905T3 (da) 2011-10-03 2022-02-28 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf
SG11201403062YA (en) 2011-12-13 2014-07-30 Engeneic Molecular Delivery Pty Ltd Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
DE12858350T1 (de) 2011-12-16 2021-10-07 Modernatx, Inc. Modifizierte mrna zusammensetzungen
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
HK1206601A1 (en) 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
US20160194625A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
EP3052122B1 (en) * 2013-10-04 2024-09-25 EnGeneIC Molecular Delivery Pty Ltd Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma
AU2015289583A1 (en) 2014-07-16 2017-02-02 Modernatx, Inc. Chimeric polynucleotides
EP3171895A1 (en) 2014-07-23 2017-05-31 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
CN107921143B (zh) 2015-06-15 2021-11-19 安吉奥开米公司 用于治疗软脑膜癌病的方法
SI3394093T1 (sl) 2015-12-23 2022-05-31 Modernatx, Inc. Metode uporabe liganda OX40, ki kodira polinukleotid
WO2017120612A1 (en) 2016-01-10 2017-07-13 Modernatx, Inc. Therapeutic mrnas encoding anti ctla-4 antibodies
AU2018270111B2 (en) 2017-05-18 2022-07-14 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
AU2019242912B2 (en) 2018-03-28 2025-07-17 Board Of Regents, The University Of Texas System Identification of epigenetic alterations in DNA isolated from exosomes
DE102018220892A1 (de) * 2018-12-04 2020-06-04 Robert Bosch Gmbh Vorrichtung und Verfahren zur Generierung von Labelobjekten für die Umgebung eines Fahrzeugs
JP2022513709A (ja) * 2018-12-10 2022-02-09 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー 非染色体性動的活性システム
US20220202950A1 (en) * 2019-05-01 2022-06-30 Engeneic Molecular Delivery Pty Ltd Compositions comprising bacterially derived intact minicells for theranostic applications
EP3986426A4 (en) * 2019-06-21 2023-10-18 Board of Regents, The University of Texas System TARGETING ALPHA3BETA1 INTEGRIN FOR THE TREATMENT OF CANCER AND OTHER DISEASES
CN111001014B (zh) * 2019-12-12 2022-04-22 四川大学华西医院 一种基于固定细菌做载体的抗肿瘤药物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030203411A1 (en) * 2001-06-05 2003-10-30 Sabbadini Roger A. Methods of minicell-based delivery
US20040005700A1 (en) * 2002-05-28 2004-01-08 Surber Mark W. Poroplasts
CN1925873A (zh) * 2004-02-02 2007-03-07 恩杰内克分子递送有限公司 经细菌来源的完整微细胞在体外和体内将药物靶向递送至哺乳动物细胞的组合物和方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0222340Y2 (enExample) 1986-11-18 1990-06-15
US6962702B2 (en) 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US6540980B1 (en) 1999-04-02 2003-04-01 Center For Molecular Medicine And Immunology Method of detecting endometriosis
MXPA01010891A (es) 1999-04-28 2002-11-07 Univ Texas Composiciones y metodos para el tratamiento contra el cancer mediante la inhibicion selectiva del factor de crecimiento endotelial vascular (vegf).
FR2793684B1 (fr) 1999-05-17 2001-08-10 Ethypharm Lab Prod Ethiques Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant
US20030194798A1 (en) * 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
WO2003033519A2 (en) * 2001-10-15 2003-04-24 Engeneic Gene Therapy Pty Limited Intact minicells as vectors for dna transfer and gene therapy in vitro and in vivo
US7332585B2 (en) * 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
ATE461713T1 (de) 2002-05-29 2010-04-15 Immunomedics Inc Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren
CA2494310A1 (en) * 2002-08-01 2004-02-12 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
US7611885B2 (en) * 2003-06-24 2009-11-03 Engeneic Molecular Delivery Pty, Ltd. Pharmaceutically compatible method for purifying intact bacterial minicells
CA2549840C (en) * 2003-12-09 2012-03-20 Engeneic Molecular Delivery Pty Ltd. Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells
US8772013B2 (en) 2004-02-02 2014-07-08 Engeneic Molecular Delivery Pty Ltd Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
US7837998B2 (en) * 2004-05-21 2010-11-23 Nathaniel Lallatin Anti-cancer activity of an anti-thymidine kinase monoclonal antibody
MX2007002294A (es) * 2004-08-26 2007-10-19 Engeneic Molecular Delivery Pty Ltd Suministro de acidos nucleicos funcionales a celulas mamiferas via minicelulas intactas, derivadas bacterialmente.
EP1861072A2 (en) 2005-03-14 2007-12-05 Massachusetts Institute Of Technology Nanocells for diagnosis and treatment of diseases and disorders
CA2646329C (en) * 2006-03-20 2018-07-03 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
PL2040725T3 (pl) * 2006-06-23 2014-08-29 Engeneic Molecular Delivery Pty Ltd Celowane dostarczanie leków, terapeutycznych kwasów nukleinowych i funkcjonalnych kwasów nukleinowych do komórek ssaczych poprzez nienaruszone uśmiercone komórki bakteryjne
RU2450832C2 (ru) 2006-10-25 2012-05-20 Конинклейке Филипс Электроникс Н.В. Контрастные вещества для детекции рака предстательной железы
LT2865755T (lt) 2007-03-30 2017-07-25 Engeneic Molecular Delivery Pty Ltd Iš bakterijų gautos, sveikos miniląstelės, apimančios reguliacinę rnr
US20100112670A1 (en) * 2008-06-25 2010-05-06 Vaxiion Therapeutics, Inc. Regulated genetic suicide mechanism compositions and methods
MX2011005967A (es) * 2008-12-05 2011-06-30 Abraxis Bioscience Llc Peptidos enlazados a sparc y usos de los mismos.
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
ES2720659T3 (es) * 2011-02-15 2019-07-23 Vaxiion Therapeutics Llc Composiciones terapéuticas y métodos para la administración dirigida, mediante minicélulas bacterianas, de moléculas bioactivas basadas en moléculas dirigidas que contienen Fc y anticuerpos
SG11201403062YA (en) * 2011-12-13 2014-07-30 Engeneic Molecular Delivery Pty Ltd Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
CN112689511A (zh) 2018-07-23 2021-04-20 安吉尼科分子传输公司 包含细菌源微细胞的组合物及其使用方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030203411A1 (en) * 2001-06-05 2003-10-30 Sabbadini Roger A. Methods of minicell-based delivery
US20040005700A1 (en) * 2002-05-28 2004-01-08 Surber Mark W. Poroplasts
CN1925873A (zh) * 2004-02-02 2007-03-07 恩杰内克分子递送有限公司 经细菌来源的完整微细胞在体外和体内将药物靶向递送至哺乳动物细胞的组合物和方法

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114099686A (zh) * 2014-07-15 2022-03-01 约翰·霍普金斯大学 源自骨髓的抑制细胞的抑制和免疫检查点阻断
CN114099686B (zh) * 2014-07-15 2024-04-16 约翰·霍普金斯大学 源自骨髓的抑制细胞的抑制和免疫检查点阻断
CN106999444A (zh) * 2014-10-03 2017-08-01 安吉尼科分子传输公司 完整的细菌衍生的囊泡对小分子化合物的增强装载
CN106999444B (zh) * 2014-10-03 2023-12-12 安吉尼科分子传输公司 完整的细菌衍生的囊泡对小分子化合物的增强装载

Also Published As

Publication number Publication date
CY1123824T1 (el) 2022-03-24
AU2017239542B2 (en) 2019-04-04
US11964021B2 (en) 2024-04-23
MX2014006967A (es) 2014-12-05
CA2858315A1 (en) 2013-06-20
KR102046042B1 (ko) 2019-11-18
LT2790668T (lt) 2020-12-28
JP6522340B2 (ja) 2019-05-29
US9844598B2 (en) 2017-12-19
AU2017239542A1 (en) 2017-10-26
DK2790668T3 (da) 2020-11-23
US20210213133A1 (en) 2021-07-15
JP6594383B2 (ja) 2019-10-23
EP2790668B1 (en) 2020-09-09
MX385832B (es) 2025-03-18
US10994014B2 (en) 2021-05-04
ES2843402T3 (es) 2021-07-16
SI2790668T1 (sl) 2021-01-29
CN109125286A (zh) 2019-01-04
HRP20201930T1 (hr) 2021-02-05
SMT202000676T1 (it) 2021-01-05
RU2664698C2 (ru) 2018-08-21
EP2790668A4 (en) 2015-07-15
HUE052136T2 (hu) 2021-04-28
EP2790668A1 (en) 2014-10-22
KR20190084349A (ko) 2019-07-16
JP2018024678A (ja) 2018-02-15
PT2790668T (pt) 2020-11-10
NZ709680A (en) 2017-03-31
TW201330860A (zh) 2013-08-01
NZ626187A (en) 2016-06-24
AU2012351743A1 (en) 2014-07-03
JP2015500328A (ja) 2015-01-05
IL233031B (en) 2019-12-31
IL233031A0 (en) 2014-07-31
US20180043027A1 (en) 2018-02-15
MX359410B (es) 2018-09-27
WO2013088250A4 (en) 2013-10-24
CA2858315C (en) 2020-05-12
AU2012351743B2 (en) 2017-07-06
RU2014128338A (ru) 2016-02-10
TWI627966B (zh) 2018-07-01
SG10201601349XA (en) 2016-03-30
KR20140102294A (ko) 2014-08-21
US20130177499A1 (en) 2013-07-11
SG11201403062YA (en) 2014-07-30
RS61161B1 (sr) 2021-01-29
WO2013088250A1 (en) 2013-06-20
HK1201473A1 (en) 2015-09-04

Similar Documents

Publication Publication Date Title
US11964021B2 (en) Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
Guimarães et al. Nanoparticles for immune cytokine TRAIL-based cancer therapy
KR102433719B1 (ko) 약물 로딩된, 이중특이성 리간드-표적화된 미니세포 및 인터페론 감마에 의한 복합 종양 치료
US20220202950A1 (en) Compositions comprising bacterially derived intact minicells for theranostic applications
Oswald et al. Drug delivery systems using surface markers for targeting cancer stem cells
HK1201473B (en) Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
NZ709680B2 (en) Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
NZ626187B2 (en) Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
BR112016007100B1 (pt) Uso de composição, composição e kit

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20141022